US2006198817A1PendingUtilityA1

Materials and methods for preventing and treating microbe-mediated epithelial disorders

44
Individually held — no corporate assignee on recordPriority: Nov 26, 2002Filed: Nov 26, 2002Published: Sep 7, 2006
Est. expiryNov 26, 2022(expired)· nominal 20-yr term from priority
Inventors:John C. Alverdy
A61P 37/06A61P 31/12A61P 31/00A61P 31/10A61P 27/16A61P 31/04A61P 17/02A61P 11/00A61P 1/04A61P 1/12A61P 13/02A61P 1/18A23K 50/20A23L 33/10A61K 31/721A23K 50/40A23K 50/10A23L 33/40A23K 20/105A23K 50/30A61K 31/765A23K 50/75A61K 31/77A61K 31/198A61K 47/34
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such ad dextran and/or essential pathogen nutrients such as L-glutantine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens such as Pseudomonas aeruginosa by administering high molecular weight polyethylene glycol as well as methods for monitoring the administration of high molecular weight polyethylene glycol, such as in methods of preventing, ameliorating or treating microbe-induced epithelial disorders, as exemplified by gut-derived sepsis. Frequently, gut-derived sepsis arises as a complication in mammals recovering from surgical intervention or suffering from a disease or disorder, providing indications of suitable animals to receive preventative treatment. Finally, the invention provides a composition comprising infant formula and polyethylene glycol and methods for using that composition.

Claims

exact text as granted — not AI-modified
1 . A method of reducing the likelihood of mortality in an animal with an abnormal condition comprising an epithelial surface at risk of developing a microbe-mediated disorder comprising administering an effective dose of polyethylene glycol (PEG) to an animal in need thereof, wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       2 . The method according to  claim 1  wherein the abnormal condition is selected from the group consisting of gut-derived sepsis, a bum injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis and pig belly.  
   
   
       3 . The method according to  claim 1  wherein the animal is selected from the group consisting of dog, cat, sheep, goat, cow, pig, chicken, horse and human.  
   
   
       4 . (canceled)  
   
   
       5 . The method according to  claim 1  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       6 .- 8 . (canceled)  
   
   
       9 . A method of inhibiting PA-I lectin/adhesin expression in an intestinal pathogen comprising administering an effective dose of polyethylene glycol (PEG) to an animal in need thereof, wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       10 . The method according to  claim 9  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       11 . A method of inhibiting intestine-induced activation of PA-I lectin/adhesin comprising administering an effective dose of polyethylene glycol (PEG) to an animal in need thereof, wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       12 . The method according to  claim 11  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       13 . A method of inhibiting C4-HSL-induced morphological change of an intestinal pathogen comprising administering an effective dose of polyethylene glycol (PEG) to an animal in need thereof, wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       14 . The method according to  claim 13  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       15 . A method of reducing virulence expression in an intestinal pathogen comprising administering an effective dose of polyethylene glycol (PEG) to an animal in need thereof, wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       16 . The method according to  claim 15  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       17 . A method of ameliorating intestinal pathogenesis by preventing formation of pathogenic quorum-sensing activation comprising administering an effective dose of polyethylene glycol (PEG) to an animal in need thereof, wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       18 . The method according to  claim 17  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       19 . A method of inhibiting bacterial cell adherence to a mammalian intestine comprising contacting the intestine with polyethylene glycol (PEG), wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       20 .- 21 . (canceled)  
   
   
       22 . The method according to  claim 19  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       23 . A method of reducing the expression of PA-I lectin/adhesin in a bacterial cell comprising contacting the bacterial cell with polyethylene glycol (PEG), wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       24 . The method according to  claim 23  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       25 . A method of reducing the likelihood of mortality in an animal exhibiting a microbe-mediated epithelial disorder comprising administering polyethylene glycol (PEG) in an amount effective to inhibit the interaction of a mammalian intestinal epithelial cell and a bacterial cell, wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       26 . The method according to  claim 25  wherein the microbe-mediated epithelial disorder is selected from the group consisting of gut-derived sepsis, a bum injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection and pouchitis.  
   
   
       27 . (canceled)  
   
   
       28 . The method according to  claim 25  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       29 . (canceled)  
   
   
       30 . The method according to  claim 25  further comprising introducing an effective amount of a compound selected from the group consisting of dextran, dextran-coated L-glutamine and dextran-coated inulin into the intestine of said animal.  
   
   
       31 .- 34 . (canceled)  
   
   
       35 . A method of preventing a disease or an abnormal condition comprising administering a composition comprising an effective dose of polyethylene glycol (PEG) to an animal, wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       36 . The method according to  claim 35  wherein the disease or abnormal condition is selected from the group consisting of swimmer's ear, acute otitis media, chronic otitis media, ventilator-associated pneumonia, gut-derived sepsis, necrotizing enterocolitis, antibiotic-induced diarrhea, pseudomembranous colitis, an inflammatory bowel disease, irritable bowel disease, neutropenic enterocolitis, pancreatitis, chronic fatigue syndrome, dysbiosis syndrome, microscopic colitis, a chronic urinary tract infection, a sexually transmitted disease, and infection.  
   
   
       37 . The method according to  claim 36  wherein the animal is selected from the group consisting of dog, cat, sheep, goat, cow, pig, chicken, horse and human.  
   
   
       38 . (canceled)  
   
   
       39 . The method according to  claim 35  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       40 .- 42 . (canceled)  
   
   
       43 . The method according to  claim 35 , wherein the composition further comprises a vehicle selected from the group consisting of a liquid solution, a topical gel, and a solution suitable for nebulizing.  
   
   
       44 . The method according to  claim 35 , wherein the composition further comprises a compound selected from the group consisting of dextran-coated L-glutamine, dextran-coated inulin, dextran-coated butyric acid, a fructo-oligosaccharide, N-acetyl-D-galactosamine, dextran-coated mannose, galactose and lactulose.  
   
   
       45 . The method according to  claim 35 , wherein the composition further comprises dextran-coated L-glutamine, dextran-coated inulin, dextran-coated butyric acid, a fructo-oligosaccharide, N-acetyl-D-galactosamine, dextran-coated mannose, galactose and lactulose.  
   
   
       46 .- 48 . (canceled)  
   
   
       49 . A method of preventing respiratory infection comprising the step of administering an effective amount of polyethylene glycol (PEG) to an animal, wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       50 . The method according to  claim 49  wherein the respiratory infection is selected from the group consisting of ventilator-associated pneumonia and infection.  
   
   
       51 . The method according to  claim 50 , wherein the agent causing said infection is selected from the group consisting of  Bacillus anthracis  and Small Pox Virus.  
   
   
       52 .- 55 . (canceled)  
   
   
       56 . A method of preventing a digestive tract disorder comprising administering an effective dose of a composition comprising polyethylene glycol (PEG) to an animal in need thereof, wherein the PEG has an average molecular weight of at least 5,000 daltons.  
   
   
       57 . The method according to  claim 56  wherein the digestive tract disorder is selected from the group consisting of neonatal necrotizing enterocolitis, antibiotic-induced diarrhea, pseudomembranous colitis, an inflammatory bowel disease, irritable bowel disease, neutropenic enterocolitis, pancreatitis, dysbiosis syndrome and microscopic colitis.  
   
   
       58 .- 68 . (canceled)  
   
   
       69 . A method of preventing loss of lactating capacity in an animal exhibiting an epithelial surface of a mammary gland at risk of developing a microbe-mediated disorder affecting milk output, comprising administering an effective dose of a polyethylene glycol (PEG), wherein the PEG has an average molecular weight of at least 5,000 daltons, to the epithelial surface of a mammary gland.  
   
   
       70 . The method according to  claim 69  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       71 . A method of preventing development of a microbe-mediated epithelial disorder in an animal of nursing age comprising administering an effective dose of polyethylene glycol (PEG), wherein the PEG has an average molecular weight of at least 5,000 daltons to the animal.  
   
   
       72 . The method according to  claim 71  wherein the PEG has an average molecular weight of at least 15,000 daltons.  
   
   
       73 . The method according to  claim 71  wherein the PEG is admixed with infant formula.  
   
   
       74 .- 75 . (canceled)

Join the waitlist — get patent alerts

Track US2006198817A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.